Curaleaf International becomes a founding member of the Cannabis-Based Medicines Association

A new UK trade association, led by licensed operators, sets out a path for cannabis-based medicines to become part of mainstream healthcare.

Curaleaf International is a founding member of the Cannabis-Based Medicines Association (CBMA), which launched on 16 November 2026. The other founding members are Glass Pharms and Wellford.

The CBMA is the first UK trade association dedicated exclusively to prescribed cannabis-based medicines. Voting rights are reserved for licensed UK operators. Its founding manifesto, Towards mainstream healthcare: Better access, higher standards, a responsible industry, sets out five priorities:

  1. Put patients first
  2. Make existing regulation work as intended
  3. Protect patients and raise standards
  4. Strengthen clinical confidence and evidence
  5. Build a responsible and sustainable industry

Specialist doctors in the UK have been able to prescribe cannabis-based medicines since November 2018. Around 95,000 patients have received a prescription since then, according to the Medical Cannabis Clinicians Society’s Good Practice Guide (August 2026). Even so, access is still concentrated in private healthcare, and NHS prescribing remains very limited.

To mark its launch, the CBMA has joined the Medical Cannabis Clinicians Society (MCCS) in writing to Professor Henrietta Hughes OBE, England’s Patient Safety Commissioner. The letter offers to work together on prescribing safeguards and standards of care. One area proposed is giving prescribers better information about the medicines their patients receive, including product composition, Certificates of Analysis and changes to formulations.

Jonathan Hodgson, UK Managing Director, Curaleaf International, said:

“Having been part of this sector from the start, from manufacturing right through to clinical care, we believe that progress in an emerging area of medicine depends on high standards and good research, and on the sector working together. The CBMA gives us a place to do that, sharing knowledge and best practice to support the delivery of the highest quality care and medication.”

Mikael Sodergren, Chief Medical Officer, Curaleaf International, said:

“Clinical decisions must rest on reliable products, transparent information and rigorous research. Giving prescribers clearer data on the medicines they prescribe, and building the real-world evidence base together in clinics, is how this field earns its place in mainstream healthcare. We look forward to contributing to that work through the CBMA.”

The CBMA will also take part in the All-Party Parliamentary Group for Medical Cannabis under Prescription.

Read the CBMA manifesto and find out more at cbma.org.uk

Latest news

Latest News
Since 2019, Curaleaf International has invested in building rigorous, peer-reviewed evidence on patient outcomes in…